ReviewCurrent diabetes reports2018
Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment.
Review in Current diabetes reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study.Diabetes, obesity & metabolism · 2022Trial
- Challenges and barriers in managing Type 2 diabetes: insights from a qualitative study of patients' experiences at a university hospital in Qassim, Saudi Arabia.Global health action · 2026Article
- Article
- The global economic burden of diabetes for 190 countries 2021-50: a macroeconomic modelling study.Nature communications · 2026Article
- The Global, regional, and national burden of type 1 diabetes mellitus-related chronic kidney disease, 1990-2021: Insights from the global burden of disease study 2021 and projections to 2050.International urology and nephrology · 2026Article
- Cost of diabetes and hypertension services delivered in primary and secondary-level government facilities in Punjab, India.BMC health services research · 2026Article
- Availability of essential medicines for non-communicable diseases: a scoping review of challenges and opportunities.BMJ global health · 2025Article
- Development of Transdermal Drug Delivery Approaches to Combat Diabetes: An Update.Current drug metabolism · 2025Review
- Pakistan's first medicine price deregulation policy: assessing its impact on prices, affordability, and availability of oral anti-diabetic medicines in private pharmacies.Frontiers in pharmacology · 2025Article
- Availability and affordability of diabetes healthcare services associated with the frequency of diabetes-related complications.BMC health services research · 2024Article
- Comorbid depression and anxiety and their association with health care resource utilization among individuals with type 1 diabetes in the United States.Journal of managed care & specialty pharmacy · 2024Article
- Barriers and facilitators to primary care for people living with HIV and diabetes in Harare.African journal of primary health care & family medicine · 2024Article
- A comprehensive survey of cancer medicines prices, availability and affordability in Ghana.PloS one · 2023Article
- Association between the Diabetes Drug Cost and Cardiovascular Events and Death in Korea: A National Health Insurance Service Database Analysis.Endocrinology and metabolism (Seoul, Korea) · 2022Observational
- Affordability of Medication Therapy in Diabetic Patients: A Scenario-Based Assessment in Iran's Health System Context.International journal of health policy and management · 2022Article
- Uptake of new antidiabetic medicines in 11 European countries.BMC endocrine disorders · 2021Article
- What Factors Hindered the Access to Essential Anticancer Medicine in Public Hospitals for the Local Population in Hubei Province, China.Frontiers in pharmacology · 2021Article
- A new look at brittle diabetes.Journal of diabetes and its complications · 2021Review
- Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.BioMed research international · 2021Article
- Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purpose of this review is to highlight the key issues with regard to the value, affordability, and availability of diabetes treatments. RECENT
findingsMany of the medicines needed to manage diabetes are available as generics and, if purchased appropriately, can be made affordable to many individuals and systems. With new treatments for diabetes, additional costs to individuals and systems need to be assessed in terms of added clinical benefit and financial impact. As healthcare finances are limited, increased spending on diabetes medicines means fewer resources for other areas of diabetes care or for the population as a whole. This increased expenditure is driven by rising prevalence as well as the cost of newer treatments. With an increasing burden of disease and changing patterns of medicines in the market, we stress the need to focus attention on ensuring access for individuals to essential medicines. Universal health care offers unique opportunity to address the issue of access to medicines and the wider issues surrounding access to diabetes care, but this will require concerted action bringing together governments, civil society and the private sector.
Indexed as
Identifiers
29907884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.